Thomas H. Waid, MD

Medical Director, Renal and Pancreas Transplantation Program

Clinical interests

  • Acute Rejection Treatment
  • Continuous Renal Replacement Therapy
  • Critical Care Nephrology
  • Kidney and Pancreas Transplantation
  • Metabolic Bone Disease
  • Monoclonal Antibodies
  • Renal Failure

Awards

Distinguished Physician Award, 2016, National Kidney Foundation


Thomas H. Waid, MD

Medical Director, Renal and Pancreas Transplantation Program

Biography

My name is Thomas H. Waid; I received my medical degree from the University of Kentucky, College of Medicine, Lexington. I completed a fellowship at the University of Kentucky, Lexington.

I am board certified by the American Board of Internal Medicine.

Faculty rank

Professor of Medicine

Education

Degree
University of Kentucky, College of Medicine, Lexington

Residency
University of Kentucky, Lexington

Fellowship
University of Kentucky, Lexington

Certifications or Special training
American Board of Internal Medicine

Nephrology, Bone & Mineral Metabolism

UK Good Samaritan Professional Arts Center
Suite 401
135 E. Maxwell St.
Lexington KY 40508-2640


UK HealthCare accepts many forms of insurance. See list of insurers »

 
  1. Waid TH, Thompson JS, Siemionow M, Brown SA. T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection. Drug Des Devel Ther. 2009; 3:205-12. PMID: 19920935.
    View in: PubMed
  2. Flynn JD, Akers WS, Jones M, Stevkovic N, Waid T, Mullett T, Jahania S. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy. 2004 Jul; 24(7):932-8. PMID: 15303457.
    View in: PubMed
  3. Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, McKeown JW, Lucas BA, Ranjan D. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis. 2003 Feb; 41(2):464-70. PMID: 12552511.
    View in: PubMed
  4. Reddy KS, Mastrangelo M, D Johnston T, Khan T, Waid T, McKeown W, Lucas B, Ranjan D. Recipient outcome following living donor kidney transplantation using kidneys procured laparoscopically. Clin Transplant. 2003; 17 Suppl 9:44-7. PMID: 12795668.
    View in: PubMed
  5. Waid TH, Thompson JS, McKeown JW, Brown SA, Sekela ME. Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study. J Heart Lung Transplant. 1997 Sep; 16(9):913-6. PMID: 9322140.
    View in: PubMed
  6. Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Transplantation. 1997 Jul 27; 64(2):274-81. PMID: 9256187.
    View in: PubMed
  7. Pescovitz MD, Barone G, Choc MG, Hricik DE, Hwang DS, Jin JH, Klein JB, Marsh CL, Min DI, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group. Transplantation. 1997 Mar 15; 63(5):778-80. PMID: 9075853.
    View in: PubMed
  8. Brown S, Lucas B, Waid T, McKeown W, Tsuchida M, Thompson J. T10B9 action: the effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response. Transplant Proc. 1997 Feb-Mar; 29(1-2):315-6. PMID: 9123017.
    View in: PubMed
  9. Brown SA, Lucas BA, Waid TH, McKeown JW, Barve S, Jackson LR, Thompson JS. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec; 10(6 Pt 2):607-13. PMID: 8996751.
    View in: PubMed
  10. Barone G, Bunke CM, Choc MG, Hricik DE, Jin JH, Klein JB, Marsh CL, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group. Transplant Proc. 1996 Aug; 28(4):2183-6. PMID: 8769194.
    View in: PubMed
  11. Barone G, Bunke CM, Choc MG, Hricik DE, Jin JH, Klein JB, Marsh CL, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group. Transplantation. 1996 Mar 27; 61(6):968-70. PMID: 8623168.
    View in: PubMed
  12. Barone G, Chang CT, Choc MG, Klein JB, Marsh CL, Meligeni JA, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation. 1996 Mar 27; 61(6):875-80. PMID: 8623152.
    View in: PubMed
  13. Waid TH, McKeown JW. Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. Transplant Proc. 1995 Oct; 27(5 Suppl 1):46. PMID: 7482820.
    View in: PubMed
  14. Lucas BA, Waid TH, Thompson JS, Brown SA, Munch LC, McKeown JW, Kryscio RJ, Prebeck RJ. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection. Transplant Proc. 1993 Feb; 25(1 Pt 1):543-5. PMID: 8438406.
    View in: PubMed
  15. Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation. 1992 Jan; 53(1):80-6. PMID: 1531095.
    View in: PubMed
  16. Waid TH, Lucas BA, Thompson JS, Munch LC, Brown S, Kryscio R, Prebeck R, VanHoy MA, Jezek D. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial. Transplant Proc. 1991 Feb; 23(1 Pt 2):1062-5. PMID: 1899152.
    View in: PubMed
  17. Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis. 1989 Nov; 14(5 Suppl 2):61-70. PMID: 2479265.
    View in: PubMed
  18. Waid TH, Lucas BA, Thompson JS, Brown S, Moore D, Amlot P, Janossy G. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody. Transplant Proc. 1989 Feb; 21(1 Pt 2):1778-84. PMID: 2652582.
    View in: PubMed

Podcasts